Muszkat M - Search Results

1

Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects.

Shaul C, Blotnick S, Muszkat M, Bialer M, Caraco Y. Shaul C, et al. Among authors: muszkat m. Mol Diagn Ther. 2017 Feb;21(1):75-83. doi: 10.1007/s40291-016-0247-7. Mol Diagn Ther. 2017. PMID: 27878474

2

Ticlopidine-induced thrombotic thrombocytopenic purpura.

Muszkat M, Shapira MY, Sviri S, Linton DM, Caraco Y. Muszkat M, et al. Pharmacotherapy. 1998 Nov-Dec;18(6):1352-5. Pharmacotherapy. 1998. PMID: 9855338 Review.

3

Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo.

Caraco Y, Muszkat M, Wood AJ. Caraco Y, et al. Among authors: muszkat m. Pharmacogenetics. 2001 Oct;11(7):587-96. doi: 10.1097/00008571-200110000-00005. Pharmacogenetics. 2001. PMID: 11668218

4

Major bleeding caused by warfarin in a genetically susceptible patient.

Bloch A, Ben-Chetrit E, Muszkat M, Caraco Y. Bloch A, et al. Among authors: muszkat m. Pharmacotherapy. 2002 Jan;22(1):97-101. doi: 10.1592/phco.22.1.97.33491. Pharmacotherapy. 2002. PMID: 11794436

5

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.

Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, Kimura S, Echizen H. Takahashi H, et al. Among authors: muszkat m. Clin Pharmacol Ther. 2003 Mar;73(3):253-63. doi: 10.1067/mcp.2003.26a. Clin Pharmacol Ther. 2003. PMID: 12621390

6

Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.

Muszkat M, Blotnik S, Elami A, Krasilnikov I, Caraco Y. Muszkat M, et al. Clin Ther. 2007 Mar;29(3):427-37. doi: 10.1016/s0149-2918(07)80081-6. Clin Ther. 2007. PMID: 17577464 Clinical Trial.

7

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

Caraco Y, Blotnick S, Muszkat M. Caraco Y, et al. Among authors: muszkat m. Clin Pharmacol Ther. 2008 Mar;83(3):460-70. doi: 10.1038/sj.clpt.6100316. Epub 2007 Sep 12. Clin Pharmacol Ther. 2008. PMID: 17851566 Clinical Trial.

8

Estimation of the warfarin dose with clinical and pharmacogenetic data.

International Warfarin Pharmacogenetics Consortium; Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. International Warfarin Pharmacogenetics Consortium, et al. N Engl J Med. 2009 Feb 19;360(8):753-64. doi: 10.1056/NEJMoa0809329. N Engl J Med. 2009. PMID: 19228618 Free PMC article.

9

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.

Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ; International Warfarin Pharmacogenetics Consortium. Limdi NA, et al. Blood. 2010 May 6;115(18):3827-34. doi: 10.1182/blood-2009-12-255992. Epub 2010 Mar 4. Blood. 2010. PMID: 20203262 Free PMC article.

10

Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.

Muszkat M, Bialer O, Blotnick S, Adar L, Xie HG, Ufer M, Cascorbi I, Caraco Y. Muszkat M, et al. Clin Ther. 2010 Feb;32(2):347-56. doi: 10.1016/j.clinthera.2010.02.008. Clin Ther. 2010. PMID: 20206792 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters